Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis

Thompson, Eric M., Hielscher, Thomas, Bouffet, Eric, Remke, Marc, Luu, Betty, Gururangan, Sridharan, McLendon, Roger E., Bigner, Darell D., Lipp, Eric S., Perreault, Sebastien, Cho, Yoon-Jae, Grant, Gerald, Kim, Seung-Ki, Lee, Ji Yeoun, Rao, Amulya A. Nageswara, Giannini, Caterina, Li, Kay Ja Wai, Ng, Ho-Keung, Yao, Yu, Kumabe, Toshihiro, Tominaga, Teiji, Grajkowska, Wieslawa A., Perek-Polnik, Marta, Low, David C. Y., Seow, Wan Tew, Chang, Kenneth T. E., Mora, Jaume, Pollack, Ian F., Hamilton, Ronald L., Leary, Sarah, Moore, Andrew S., Ingram, Wendy J., Hallahan, Andrew R., Jouvet, Anne, Fevre-Montange, Michelle, Vasiljevic, Alexandre, Faure-Conter, Cecile, Shofuda, Tomoko, Kagawa, Naoki, Hashimoto, Naoya, Jabado, Nada, Weil, Alexander G., Gayden, Tenzin, Wataya, Takafumi, Shalaby, Tarek, Grotzer, Michael, Zitterbart, Karel, Sterba, Jaroslav, Kren, Leos, Hortobagyi, Tibor, Klekner, Almos, Laszlo, Bognár, Pocza, Tímea, Hauser, Peter, Schuller, Ulrich, Jung, Shin, Jang, Woo-Youl, French, Pim J., Kros, Johan M., van Veelen, Marie-Lise C., Massimi, Luca, Leonard, Jeffery R., Rubin, Joshua B., Vibhakar, Rajeev, Chambless, Lola B., Cooper, Michael K., Thompson, Reid C., Faria, Claudia C., Carvalho, Alice, Nunes, Sofia, Pimentel, Jose, Fan, Xing, Muraszko, Karin M., Lopez-Aguilar, Enrique, Lyden, David, Garzia, Livia, Shih, David J. H., Kijima, Noriyuki, Schneider, Christian, Adamski, Jennifer, Northcott, Paul A., Kool, Marcel, Jones, David T. W., Chan, Jennifer A., Nikolic, Ana, Garre, Maria Luisa, Van Meir, Erwin G., Osuka, Satoru, Olson, Jeffery J., Jahangiri, Arman, Castro, Brandyn A., Gupta, Nalin, Weiss, William A., Moxon-Emre, Iska, Mabbott, Donald J., Lassaletta, Alvaro, Hawkins, Cynthia E., Tabori, Uri, Drake, James, Kulkarni, Abhaya, Dirks, Peter, Rutka, James T., Korshunov, Andrey, Pfister, Stefan M., Packer, Roger J., Ramaswamy, Vijay and Taylor, Michael D. (2016) Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. The Lancet Oncology, 17 4: 484-495. doi:10.1016/S1470-2045(15)00581-1

Author Thompson, Eric M.
Hielscher, Thomas
Bouffet, Eric
Remke, Marc
Luu, Betty
Gururangan, Sridharan
McLendon, Roger E.
Bigner, Darell D.
Lipp, Eric S.
Perreault, Sebastien
Cho, Yoon-Jae
Grant, Gerald
Kim, Seung-Ki
Lee, Ji Yeoun
Rao, Amulya A. Nageswara
Giannini, Caterina
Li, Kay Ja Wai
Ng, Ho-Keung
Yao, Yu
Kumabe, Toshihiro
Tominaga, Teiji
Grajkowska, Wieslawa A.
Perek-Polnik, Marta
Low, David C. Y.
Seow, Wan Tew
Chang, Kenneth T. E.
Mora, Jaume
Pollack, Ian F.
Hamilton, Ronald L.
Leary, Sarah
Moore, Andrew S.
Ingram, Wendy J.
Hallahan, Andrew R.
Jouvet, Anne
Fevre-Montange, Michelle
Vasiljevic, Alexandre
Faure-Conter, Cecile
Shofuda, Tomoko
Kagawa, Naoki
Hashimoto, Naoya
Jabado, Nada
Weil, Alexander G.
Gayden, Tenzin
Wataya, Takafumi
Shalaby, Tarek
Grotzer, Michael
Zitterbart, Karel
Sterba, Jaroslav
Kren, Leos
Hortobagyi, Tibor
Klekner, Almos
Laszlo, Bognár
Pocza, Tímea
Hauser, Peter
Schuller, Ulrich
Jung, Shin
Jang, Woo-Youl
French, Pim J.
Kros, Johan M.
van Veelen, Marie-Lise C.
Massimi, Luca
Leonard, Jeffery R.
Rubin, Joshua B.
Vibhakar, Rajeev
Chambless, Lola B.
Cooper, Michael K.
Thompson, Reid C.
Faria, Claudia C.
Carvalho, Alice
Nunes, Sofia
Pimentel, Jose
Fan, Xing
Muraszko, Karin M.
Lopez-Aguilar, Enrique
Lyden, David
Garzia, Livia
Shih, David J. H.
Kijima, Noriyuki
Schneider, Christian
Adamski, Jennifer
Northcott, Paul A.
Kool, Marcel
Jones, David T. W.
Chan, Jennifer A.
Nikolic, Ana
Garre, Maria Luisa
Van Meir, Erwin G.
Osuka, Satoru
Olson, Jeffery J.
Jahangiri, Arman
Castro, Brandyn A.
Gupta, Nalin
Weiss, William A.
Moxon-Emre, Iska
Mabbott, Donald J.
Lassaletta, Alvaro
Hawkins, Cynthia E.
Tabori, Uri
Drake, James
Kulkarni, Abhaya
Dirks, Peter
Rutka, James T.
Korshunov, Andrey
Pfister, Stefan M.
Packer, Roger J.
Ramaswamy, Vijay
Taylor, Michael D.
Title Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis
Journal name The Lancet Oncology   Check publisher's open access policy
ISSN 1474-5488
Publication date 2016-04
Year available 2016
Sub-type Article (original research)
DOI 10.1016/S1470-2045(15)00581-1
Open Access Status Not Open Access
Volume 17
Issue 4
Start page 484
End page 495
Total pages 12
Place of publication London, United Kingdom
Publisher Lancet Publishing Group
Collection year 2017
Language eng
Formatted abstract
Background: Patients with incomplete surgical resection of medulloblastoma are controversially regarded as having a marker of high-risk disease, which leads to patients undergoing aggressive surgical resections, so-called second-look surgeries, and intensified chemoradiotherapy. All previous studies assessing the clinical importance of extent of resection have not accounted for molecular subgroup. We analysed the prognostic value of extent of resection in a subgroup-specific manner.

Methods: We retrospectively identified patients who had a histological diagnosis of medulloblastoma and complete data about extent of resection and survival from centres participating in the Medulloblastoma Advanced Genomics International Consortium. We collected from resections done between April, 1997, and February, 2013, at 35 international institutions. We established medulloblastoma subgroup affiliation by gene expression profiling on frozen or formalin-fixed paraffin-embedded tissues. We classified extent of resection on the basis of postoperative imaging as gross total resection (no residual tumour), near-total resection (<1·5 cm2 tumour remaining), or sub-total resection (≥1·5 cm2 tumour remaining). We did multivariable analyses of overall survival and progression-free survival using the variables molecular subgroup (WNT, SHH, group 4, and group 3), age (<3 vs ≥3 years old), metastatic status (metastases vs no metastases), geographical location of therapy (North America/Australia vs rest of the world), receipt of chemotherapy (yes vs no) and receipt of craniospinal irradiation (<30 Gy or >30 Gy vs no craniospinal irradiation). The primary analysis outcome was the effect of extent of resection by molecular subgroup and the effects of other clinical variables on overall and progression-free survival.

Findings: We included 787 patients with medulloblastoma (86 with WNT tumours, 242 with SHH tumours, 163 with group 3 tumours, and 296 with group 4 tumours) in our multivariable Cox models of progression-free and overall survival. We found that the prognostic benefit of increased extent of resection for patients with medulloblastoma is attenuated after molecular subgroup affiliation is taken into account. We identified a progression-free survival benefit for gross total resection over sub-total resection (hazard ratio [HR] 1·45, 95% CI 1·07–1·96, p=0·16) but no overall survival benefit (HR 1·23, 0·87–1·72, p=0·24). We saw no progression-free survival or overall survival benefit for gross total resection compared with near-total resection (HR 1·05, 0·71–1·53, p=0·8158 for progression-free survival and HR 1·14, 0·75–1·72, p=0·55 for overall survival). No significant survival benefit existed for greater extent of resection for patients with WNT, SHH, or group 3 tumours (HR 1·03, 0·67–1·58, p=0·89 for sub-total resection vs gross total resection). For patients with group 4 tumours, gross total resection conferred a benefit to progression-free survival compared with sub-total resection (HR 1·97, 1·22–3·17, p=0·0056), especially for those with metastatic disease (HR 2·22, 1·00–4·93, p=0·050). However, gross total resection had no effect on overall survival compared with sub-total resection in patients with group 4 tumours (HR 1·67, 0·93–2·99, p=0·084).

Interpretation: The prognostic benefit of increased extent of resection for patients with medulloblastoma is attenuated after molecular subgroup affiliation is taken into account. Although maximum safe surgical resection should remain the standard of care, surgical removal of small residual portions of medulloblastoma is not recommended when the likelihood of neurological morbidity is high because there is no definitive benefit to gross total resection compared with near-total resection.

Funding: Canadian Cancer Society Research Institute, Terry Fox Research Institute, Canadian Institutes of Health Research, National Institutes of Health, Pediatric Brain Tumor Foundation, and the Garron Family Chair in Childhood Cancer Research.
Keyword Medulloblastoma
Surgical resection
Metastatic disease
Craniospinal radiation
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
Admin only - CHRC
Child Health Research Centre Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 4 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 22 Mar 2016, 01:29:53 EST by System User on behalf of Learning and Research Services (UQ Library)